VBI Vaccines (NASDAQ:VBIV – Get Free Report) was upgraded by StockNews.com to a “sell” rating in a note issued to investors on Wednesday. VBI Vaccines Trading Down 4.7 % Shares of VBIV stock traded down $0.06 during mid-day trading on Wednesday, hitting $1.22. 270,028 shares of the company’s stock were exchanged, compared to its average […]
VBI Vaccines Inc. (NASDAQ:VBIV – Get Free Report) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totalling 402,000 shares, a growth of 66.4% from the June 30th total of 241,600 shares. Based on an average trading volume of 1,230,000 shares, the short-interest ratio […]
VBI Vaccines Inc. (NASDAQ:VBIV – Get Free Report) Director Steven Gillis purchased 609,090 shares of VBI Vaccines stock in a transaction that occurred on Monday, July 10th. The stock was acquired at an average price of $1.65 per share, with a total value of $1,004,998.50. Following the transaction, the director now owns 1,043,292 shares in […]
By Stephen Nakrosis VBI Vaccines and Brii Biosciences said Wednesday they agreed to expand their Hepatitis B partnership and will address both prevention and.
23.06.2023 - VBI Vaccines Inc. (Nasdaq: VBIV) ( VBI or the Company ), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of . Seite 1